BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal

BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal

Key Points BioStem is shifting toward surgical and hospital applications following its BioTissue asset acquisition, with 87% of current revenue tied to surgical procedural reimbursement versus 13% from product-based reimbursement. Hospital revenue rose to $6.7 million in the second quarter, while the company guided for fiscal 2026 revenue of $26 million to $29 million. The company is targeting urology, foot and ankle, orthopedics and other surgical specialties, supported by clinical publications and four GPO contracts covering about two-thirds of U.S. hospital beds. It plans to expand its sales force and publish additional clinical evidence in 2026. BioStem plans to bring Neox and Clarix manufacturing in-house at its Florida facility by the first half of 2027, aiming to recover margins that fell to 61% under the current cost-plus arrangement. Second-quarter revenue was $7.9 million, but the company reported a $9 million GAAP net loss and ended the quarter with $7 million in cash.

BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility. Chairman and CEO Jason Matuszewski said the company uplisted to the Nasdaq Capital Market on Aug. 7 and now operates as a substantially different business than it did 18 months ago. BioStem develops perinatal tissue-based allografts derived from donated placental and umbilical cord tissue for surgical and advanced wound-care uses. The company guided for fiscal 2026 revenue of $26 million to $29 million, raising the low end of its prior $25 million-to-$29 million outlook. Matuszewski said BioStem has more than 10 commercial products, more than 60 direct and independent sales representatives, four group purchasing organization contracts, and manufacturing capacity estimated at four times its current usage.

Matuszewski characterized BioStem’s acquisition of BioTissue assets as a strategic transformation rather than a simple product addition. Before the transaction, BioStem was centered on wound care, physician offices and product-specific reimbursement from the Centers for Medicare & Medicaid Services. Following the acquisition, the company has expanded into hospitals and surgical settings, with exposure to commercial payers as well as CMS reimbursement. According to Matuszewski, 87% of BioStem’s current revenue is tied to surgical procedural reimbursement under diagnosis-related groups, while 13% is product-based reimbursement. He said this reduces the company’s reliance on CMS wound-care pricing. Hospital revenue reached $6.7 million in the second quarter, compared with $5.7 million in the first quarter. Physician-office revenue was $1.1 million, up from $800,000 sequentially. The acquired portfolio includes the Neox and Clarix product families, which Matuszewski said were the primary contributors to second-quarter revenue. The company’s four GPO contracts cover roughly two-thirds of U.S. hospital beds, Matuszewski said, though he emphasized that contracts provide purchasing eligibility rather than guaranteed sales. Hospitals still require physician interest and value analysis committee approval.

BioStem estimates its total addressable U.S. market at $26 billion, including approximately $11 billion across surgical specialties such as orthopedics, foot and ankle, spine, urology and colorectal procedures. The company’s product platforms include dry, hydrated and cryopreserved tissue formats. Matuszewski highlighted urology as a...